Tapering Off Antipsychotics
Antipsychotics — Seroquel (quetiapine), Zyprexa (olanzapine), Risperdal (risperidone), Abilify (aripiprazole), Latuda (lurasidone), and others — were originally developed for serious psychiatric conditions, but in the last two decades have been prescribed for a much wider range of issues: depression, anxiety, sleep, mood instability, irritability, behavioral concerns, and many off-label uses. A significant number of people now on antipsychotics were started on them during a hospitalization, a difficult medication switch, or a period when sleep had completely fallen apart — and were continued on them long after that original situation resolved.
This page is for the people who are now wondering whether they still need the medication, what stopping might involve, and whether anyone is going to take that question seriously.
If you're in that position, the question itself is reasonable. The conversation about whether and how to taper an antipsychotic is a clinical one — individual, careful, and worth having with someone who treats it as a real decision rather than an automatic no.
Why Antipsychotics Can Be Hard to Stop
Antipsychotics primarily act on dopamine receptors, with additional effects on serotonin, histamine, and other systems depending on the specific medication. Over time, the brain adapts to the presence of the medication. Dopamine receptors upregulate — meaning the brain produces more of them, or makes them more sensitive — in response to the medication's blocking effect. Other neurotransmitter systems shift in parallel.
When the medication is reduced too quickly, the dopamine system can be left in a state of relative overactivity, because the receptor changes that developed during medication use do not reverse at the same speed the medication leaves the system. The result can be a range of withdrawal symptoms, and in some cases a phenomenon the literature describes as supersensitivity psychosis — a return or emergence of psychotic-like symptoms that reflects this receptor adaptation, rather than a true return of the original condition.
This is one of the reasons antipsychotic tapering needs to be approached slowly and individually. A rapid taper can produce symptoms that get interpreted as relapse, leading to the medication being restarted at a higher dose, when what was actually happening was the nervous system reacting to the speed of the reduction.
What Hyperbolic Tapering Means for Antipsychotics
The same non-linear pharmacology that shapes SSRI, SNRI, and benzodiazepine tapering applies to antipsychotic tapering as well. The relationship between antipsychotic dose and dopamine D2 receptor occupancy is not linear. At higher doses, large reductions affect only a small percentage of receptor binding. At lower doses, the same size reduction can affect a much larger percentage. This is why the final stretch of an antipsychotic taper — the last few milligrams — is often where the most difficulty appears.
Hyperbolic tapering uses percentage-based reductions of the current dose, with progressively smaller absolute amounts as the dose drops. For antipsychotics this often involves:
Liquid formulations or compounded doses to allow precise small reductions
Tablet splitting or careful weighing where the medication and formulation allow
Long holds between reductions when symptoms warrant
Individualized pacing — the taper follows the person, not a fixed timeline
Particular care in the lower-dose range, where receptor effects per milligram become more significant
Antipsychotic tapers, when undertaken, tend to take many months to a year or more, depending on the medication, the dose, the duration of use, and the person's history.
A Note on Supersensitivity Psychosis and Tardive Symptoms
Two phenomena specific to antipsychotic use are worth naming directly, because both are described in the deprescribing literature and both can be misidentified when they appear.
Supersensitivity psychosis is a pattern described in the literature in which psychotic-like symptoms emerge during or after antipsychotic withdrawal, reflecting the dopamine receptor adaptations that developed during medication use. The pattern is distinct from a return of the original condition, though on the surface the two can look similar. Recognizing the distinction matters because the response to each is different.
Tardive symptoms — including tardive dyskinesia and tardive dysphoria — refer to movement, mood, or other symptoms that can persist after antipsychotic use and that are thought to reflect long-term changes in the neurotransmitter systems the medication acted on. These are described in the antipsychotic literature and are part of why the conversation about whether to taper, and how, is taken seriously rather than rushed.
Neither of these phenomena is something to be alarmed about reading on a webpage. They are mentioned here because they are part of what an honest conversation about antipsychotic tapering includes, and because being able to name them is often the first step toward not feeling alone with them if they are part of the picture.
Common Symptoms During an Antipsychotic Taper
Antipsychotic withdrawal can affect multiple body systems. Some of the more commonly reported symptoms include:
Insomnia — often pronounced, especially with medications that were sedating
Anxiety, sometimes with a quality that is more physical than the original
Inner restlessness or akathisia
Return or emergence of intrusive or unusual thoughts
Mood changes — irritability, emotional reactivity, low mood, or mood swings
Sensory sensitivity to sound, light, or other stimuli
Nausea, appetite changes, or gastrointestinal upset
Sweating, temperature dysregulation, or autonomic symptoms
Heart palpitations or changes in heart rate
Movement-related symptoms — tremor, muscle tension, or other motor changes
Cognitive symptoms — brain fog, memory issues, slowed thinking
Vivid or disturbing dreams
The pattern varies widely depending on the specific antipsychotic, the dose, and the individual. Some symptoms reflect the medication's secondary effects coming off, such as histamine or serotonin effects from medications like quetiapine or olanzapine. Others reflect the primary dopamine system recalibrating.
What Protracted Withdrawal Can Look Like
As with other psychiatric medication classes, the majority of withdrawal symptoms from antipsychotics resolve over weeks to a few months. For a smaller group, symptoms persist longer. The deprescribing literature refers to this as protracted withdrawal, and the pattern is often the same windows-and-waves rhythm described with other medications — stretches of relative relief broken by waves of returning symptoms, sometimes without clear trigger.
With antipsychotics specifically, the protracted course can also include the supersensitivity and tardive patterns described above. Distinguishing these from a return of an original condition is not always simple on the surface, but the timing, the symptom features, and the relationship to dose changes usually offer clues that careful clinical attention can pick up.
How I Approach Antipsychotic Tapering
My approach to antipsychotic tapering follows the same four principles I apply to all psychiatric medication tapering, with adjustments specific to this class.
Stabilization before tapering. Tapering from an unstable place — recent dose changes, recent hospitalization, ongoing acute symptoms — is generally not the right starting point. The first step is often stability at the current dose, with attention to sleep, nutrition, and overall nervous system regulation, before any reduction is considered.
Hyperbolic tapering when tapering is appropriate. Percentage-based reductions, with extra attention to the lower-dose range where receptor effects per milligram become more significant. Slower than standard tapers, and individualized to the person's history.
The whole person. Antipsychotics interact with metabolic health in ways that are particularly important — many of these medications affect weight, glucose, lipids, and metabolic function. Metabolic recovery is often part of the tapering conversation, both for general health and because metabolic state influences nervous system stability.
Real informed consent. A clear, unhurried conversation about whether tapering is appropriate, what it may involve, what the realistic timeline looks like, what supersensitivity and tardive phenomena can look like, and what the alternatives are. No pressure to taper. No pressure not to.
Who This Is and Isn't a Fit For
This work is a fit for people who have been on an antipsychotic — often for an off-label indication, often for longer than was originally planned — and who want to have a careful conversation about whether tapering is appropriate, and how to do it if so. It is a fit for people who are willing to track symptoms, communicate during the process, and approach the taper as a collaborative clinical decision rather than a guarantee of a particular outcome.
It is not a fit for people in acute psychiatric crisis, people who need inpatient-level care, people currently in a destabilized state that needs a higher level of monitoring than an outpatient practice can provide, or people who are looking for a fast taper. It is also not a fit for people who want to start new psychiatric medications — this practice focuses on stabilization, tapering, and metabolic mental health, not on initiating new prescriptions.
For people with a clear diagnosis of a primary psychotic disorder who are currently stable on antipsychotic medication, the decision about whether to taper is a careful and individual one. That conversation is welcome, but the outcome is not predetermined — sometimes the right clinical answer is to continue the medication.
Frequently Asked Questions
Should everyone on an antipsychotic taper off?
No. The decision about whether to taper is individual and depends on the original reason for the medication, the current clinical picture, the person's history, the dose and duration of use, and what the person is hoping to accomplish. For some people, tapering is appropriate. For others, continuing the medication is the right answer. The conversation is the point.
How long does an antipsychotic taper take?
There is no universal answer. Many antipsychotic tapers take many months to a year or more. For people with longer medication histories or more sensitive nervous systems, longer is sometimes appropriate. Length depends on the medication, the dose, how long it has been taken, and how the nervous system responds along the way.
What's the difference between withdrawal and relapse with an antipsychotic?
This is one of the more clinically important questions in antipsychotic tapering. Withdrawal symptoms — including supersensitivity phenomena — and a return of an original condition can look similar on the surface, but they tend to differ in timing, in the specific features of the symptoms, and in how they relate to dose changes. Distinguishing them is part of what careful clinical oversight is for.
What about tardive dyskinesia?
Tardive dyskinesia is a known potential consequence of antipsychotic use. Concerns about possible tardive symptoms are legitimate clinical concerns and are part of what an honest conversation about antipsychotic use, continuation, or tapering includes. Specific assessment of movement symptoms is part of the clinical work when tardive concerns are present.
I'm on more than one medication. Can I still taper my antipsychotic?
Yes, with care. Polypharmacy tapering involving an antipsychotic is common in this work, and the order of tapering matters. The decision about which medication to taper first depends on the overall picture, and is made individually rather than to a fixed protocol.
What if my antipsychotic was prescribed off-label?
Many antipsychotics are prescribed for indications other than psychotic disorders — sleep, anxiety, mood, irritability, and others. The original reason for prescription matters in the tapering conversation, but it does not automatically determine the answer. The taper plan is built around the individual, not the original prescribing context.
Next Steps
If you live in Texas and want to talk about whether this approach is the right fit for you, the next step is a 15-minute discovery meeting. This is a brief conversation — not a clinical evaluation — to see if my approach feels like the right match for what you're looking for.
If you live outside Texas, I cannot provide clinical care, but I offer an education-only coaching membership that may be helpful as you work with your own prescriber.
[Schedule a Discovery Meeting]
Learn About Out-of-State Coaching
Other Medication Classes